SinoMab BioScience's (HKG:3681) phase 1B China clinical trial of its SM17 drug for moderate-to-severe atopic dermatitis reached its primary endpoints, according to a Monday filing with the Hong Kong bourse.

The drug was well-tolerated during the 16-week trial and follow-up period and showed no serious adverse events, the filing said.

SM17 also showed skin healing effects, while lower doses of the drug showed relief from pruritus or itching compared with those treated with a placebo, the filing said.